$INDP

Indaptus Therapeutics, Inc. (INDP): Entry into a Material Definitive Agreement

Indaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On August 28, 2026, Indaptus Therapeutics, Inc. (the “ Company ”) entered into an Amended and Restated At the Market Offering Agreement (the “ Sales Agreement ”) with H.C. Wainwright & Co., LLC (“ Wainwright ”), which amends

Original reporting
Published Sep 1, 2026, 11:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 11:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$INDP
Neutral
high confidence
Mentioned
$INDP
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$INDPNeutralMed
01

Why it matters

The capital raise provides liquidity for ongoing clinical programs but introduces dilution risk, likely causing short‑term price movement.

02

Market read

Primary disclosure of a $100 M ATM offering for a micro‑cap biotech, a material corporate action that may affect share price and sector financing trends.

03

What to watch

Potential restrictions on use of proceeds and market appetite for additional biotech equity in a high‑volatility environment.

Relevance 6/10Novelty 8/10Timing: filing disclosed on Sep 1 2026, effective immediately

Background

Indaptus Therapeutics entered an amended and restated At‑the‑Market Offering Agreement with H.C. Wainwright, superseding its 2022 agreement and authorizing up to $100 M of common stock sales.

Company-level read

Ticker impact

$INDPNeutralHigh confidence
Context

Indaptus Therapeutics filed an 8‑K reporting an amended ATM offering agreement allowing up to $100 million of new common stock to be sold.

Expected impact

Short‑term volatility expected; possible modest upside if proceeds fund growth milestones.

Evidence & confidence

The filing is the first public disclosure of a sizable $100 M capital raise, a material corporate action for a micro‑cap biotech.

Market effects

May signal increased financing activity in the biotech sector, prompting peers to consider similar ATM structures.

Limited to U.S. biotech investors; no broader regional effect.

Low; impact confined to the company and niche biotech investors.

Counterpoint

The $100 M raise could overly dilute existing shareholders without guaranteeing successful product milestones.

Key entities

  • Indaptus Therapeutics, Inc.

    Biotech firm filing the ATM offering agreement.

  • H.C. Wainwright & Co., LLC

    Sales agent for the ATM offering.

Related articles

$INDPMed

Indaptus Therapeutics, Inc. (INDP): Results of Operations and Financial Condition

Indaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update NEW YORK (August 13, 2026) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a biotechnology company dedicated to immunotherapy research, today

$INDPMedAI 8/10

Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Indaptus Therapeutics (Nasdaq: INDP) reported Q2 2026 results and a corporate update. It raised about $12.0 million via a June 17 private placement at $0.60 per share. The company discontinued further Decoy20 enrollment and has no active clinical programs. Q2 R&D fell to ~$0.4M and net loss to ~$1.8M. Cash and short-term investments were ~$11.6M at June 30.